Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
LUNG 
Pulmonx Corp (LUNG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: LUNG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $6.75
1 Year Target Price $6.75
| 4 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -62.99% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 69.27M USD | Price to earnings Ratio - | 1Y Target Price 6.75 |
Price to earnings Ratio - | 1Y Target Price 6.75 | ||
Volume (30-day avg) 7 | Beta 0.43 | 52 Weeks Range 1.47 - 9.37 | Updated Date 09/15/2025 |
52 Weeks Range 1.47 - 9.37 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.34 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -62.88% | Operating Margin (TTM) -62.05% |
Management Effectiveness
Return on Assets (TTM) -21.57% | Return on Equity (TTM) -66.88% |
Valuation
Trailing PE - | Forward PE 28.33 | Enterprise Value 41872145 | Price to Sales(TTM) 0.77 |
Enterprise Value 41872145 | Price to Sales(TTM) 0.77 | ||
Enterprise Value to Revenue 0.46 | Enterprise Value to EBITDA -5.62 | Shares Outstanding 40746600 | Shares Floating 39663513 |
Shares Outstanding 40746600 | Shares Floating 39663513 | ||
Percent Insiders 4.27 | Percent Institutions 89.55 |
Upturn AI SWOT
Pulmonx Corp
Company Overview
History and Background
Pulmonx Corp. was founded in 1995. It focuses on developing and commercializing minimally invasive medical devices for the treatment of lung diseases. A significant milestone was the FDA approval of the Zephyr Endobronchial Valve in 2018. They have evolved to become a leader in interventional pulmonology.
Core Business Areas
- Lung Volume Reduction: Pulmonx's primary business is providing solutions for lung volume reduction in patients with severe emphysema, a form of COPD. The Zephyr Valve is their core product for this purpose.
Leadership and Structure
The leadership team consists of seasoned executives with experience in medical device development and commercialization. The company has a functional organizational structure with departments focused on R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- Zephyr Endobronchial Valve: The Zephyr Valve is a minimally invasive device used to reduce lung volume in patients with severe emphysema. This improves breathing by redirecting air from damaged areas of the lung. Competitors include traditional lung volume reduction surgery and other interventional bronchoscopic procedures. In 2023 the company earned $63.4 million in revenue related to this product
Market Dynamics
Industry Overview
The medical device industry for respiratory care is growing due to an aging population and increasing prevalence of COPD. Interventional pulmonology is a rapidly evolving field.
Positioning
Pulmonx is a leader in minimally invasive lung volume reduction. Its competitive advantage lies in the proven clinical efficacy of the Zephyr Valve and its established presence in the interventional pulmonology market.
Total Addressable Market (TAM)
The estimated TAM for Pulmonx is approximately $4 billion, representing the potential market for treating severe emphysema patients using minimally invasive techniques. Pulmonx is positioned to capture a significant share of this TAM.
Upturn SWOT Analysis
Strengths
- Proven clinical efficacy of Zephyr Valve
- Established market presence in interventional pulmonology
- Strong intellectual property portfolio
- Minimally invasive alternative to surgery
Weaknesses
- Reliance on a single core product (Zephyr Valve)
- Reimbursement challenges in some markets
- High upfront costs of the Zephyr Valve system
- Dependence on physician training and adoption
Opportunities
- Expanding indications for Zephyr Valve
- Geographic expansion into new markets
- Development of new products for other respiratory diseases
- Partnerships with hospitals and pulmonology practices
Threats
- Competition from established medical device companies
- Changes in reimbursement policies
- Technological advancements that could render Zephyr Valve obsolete
- Adverse events or safety concerns related to Zephyr Valve
Competitors and Market Share
Key Competitors
- BSX
- MRK
- JNJ
Competitive Landscape
Pulmonx's advantage lies in its specialization in minimally invasive lung volume reduction. However, larger medical device companies like Boston Scientific (BSX), Merck (MRK), and Johnson & Johnson (JNJ) have broader product portfolios and greater financial resources.
Growth Trajectory and Initiatives
Historical Growth: Pulmonx has experienced significant revenue growth in recent years, driven by increased adoption of the Zephyr Valve.
Future Projections: Analysts project continued revenue growth for Pulmonx, driven by geographic expansion and increased market penetration. However, profitability is not expected in the near term.
Recent Initiatives: Recent initiatives include expanding sales and marketing efforts in Europe and Asia, conducting clinical trials to support new indications, and developing new technologies for respiratory care.
Summary
Pulmonx is a growing medical device company with a leading product in the minimally invasive lung volume reduction space. While the company has experienced revenue growth, it still needs to achieve profitability. The company should focus on maintaining its competitive advantage and expanding into new markets while closely monitoring competitors and reimbursement policies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- Press Releases
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. The information is based on publicly available sources and is subject to change without notice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pulmonx Corp
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2020-10-01 | CEO, President & Director Mr. Steven S. Williamson | ||
Sector Healthcare | Industry Medical Devices | Full time employees 291 | Website https://pulmonx.com |
Full time employees 291 | Website https://pulmonx.com | ||
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.